Paclitaxel

erb-b2 receptor tyrosine kinase 2 ; Homo sapiens







381 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
251 18805633 The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. 2009 Jan 18 2
252 19042015 The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. 2009 Feb 5
253 19118059 Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. 2009 Jan 1 1
254 19228734 Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. 2009 Feb 15 7
255 19258951 Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. 2009 Jan 4
256 19295274 [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response]. 2009 Mar 2
257 19331197 Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. 2009 Feb 1
258 19372587 ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. 2009 Apr 5
259 19632322 Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. 2009 Oct 8 4
260 19691751 Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. 2009 Aug 2
261 19720916 Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. 2009 Oct 1 1
262 19755824 [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer]. 2009 Sep 1
263 19794992 Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. 2009 Oct 3
264 19858400 Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. 2009 Nov 20 1
265 19887543 A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. 2009 Nov 3
266 19918289 Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature. 2009 Sep 15 1
267 20062660 Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. 2009 Dec 4 1
268 17468948 HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. 2008 Mar 2
269 17953985 Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. 2008 Feb 1
270 18364725 HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy. 2008 May 1
271 18365200 Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. 2008 Nov 1
272 18375893 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. 2008 Apr 1 2
273 18685414 Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. 2008 Sep 2
274 18766004 Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. 2008 Oct 4
275 18955454 Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. 2008 Dec 1 2
276 18985033 Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. 2008 Dec 2 1
277 19106581 [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel]. 2008 Nov 1
278 16850247 Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. 2007 Mar 1
279 17200359 Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. 2007 Jan 1 2
280 17220672 [Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response]. 2007 Jan 1
281 17343796 [Apoptotic effect of the combined treatment of engineered antibody with paclitaxel on BT474 cells]. 2007 Mar 6
282 17465239 Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. 2007 Mar-Apr 2
283 17586082 Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. 2007 Jul 31 1
284 17647266 Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. 2007 Sep 15 1
285 17660958 The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. 2007 Feb 3
286 17828616 Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. 2007 Dec 3
287 17879382 Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1. 2007 Nov 4
288 17928597 HER2 and response to paclitaxel in node-positive breast cancer. 2007 Oct 11 4
289 17987122 HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. 2007 Nov 7 1
290 18022396 Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. 2007 Dec 22 1
291 18038883 When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? 2007 Sep-Oct 1
292 18083698 Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. 2007 Dec 1
293 18086299 CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. 2007 1
294 16467098 Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. 2006 Feb 1 1
295 16580691 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. 2006 May 15 4
296 16764747 Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression. 2006 Apr 1
297 16782917 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. 2006 Jun 20 1
298 16847284 Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. 2006 Aug 10 1
299 16969027 [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy]. 2006 Sep 3
300 17146157 Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience. 2006 1